Share on LinkedInShare on LinkedIn

ARTICLE · 16 JUNE 2013

The US Supreme Court rules on gene patents

Life sciences patents must be drafted carefully to ensure that they meet the new US patentability threshold requirements.

AustraliaIntellectual Property

In its long-awaited landmark decision in the case of Association for Molecular Pathology v. Myriad Genetics Inc., the U.S. Supreme Court has unanimously held that naturally occurring DNA sequences are products of nature and not patent eligible merely because they have been isolated. However, the Court also found that artificially created DNA sequences, such as cDNA, are eligible for patent protection because they do not occur naturally.

The Court's decision can be found at the following link:
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf.

The decision represents a compromise position that was proposed during oral arguments in April 2013 by the Department of Justice Solicitor General, Donald Verrilli, Jr. and effectively takes the U.S. out of line with the current laws in relation to gene patents that currently exist in Europe and Australia.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from